How much does Sofosbuvir and Velpatasvir (Epclusa) cost?

Sofosbuvir Velpatasvir (Epclusa) is a drug containing Sofosbuvir (Sofosbuvir) Oral fixed-dose combination tablets with (velpatasvir), sofosbuvir is a nucleotide analogHCV NS5B polymerase inhibitor, velpatasvir is anNS5A inhibitor. Sofosbuvir and velpatasvir are prescription medicines indicated for the treatment of adults with chronic hepatitis C (Hep C) genotypes 1-6 infection with or without cirrhosis (compensation).

The combination of sofosbuvir and velpatasvir provides a much-needed option for patients with HCV genotype 3 infection, including those with compensated cirrhosis lacking the Y93H resistance-associated variant. Compared with regimens containing hepatitis C virus protease inhibitors, the combination of sofosbuvir and velpatasvir can be safely used in patients with decompensated cirrhosis. Concomitant use of acid reducing agents, especially proton pump inhibitors, can significantly reduce the levels of the combination.

The original drug of sofosbuvir and velpatasvir has been launched in China and has entered the scope of Class B medical insurance. The domestic trade name is protonsa, and the specification is (400mg+100mg) * 28 tablets. The price per box is about RMB 4,000. The original drug of sofosbuvir and velpatasvir has also been launched overseas. There are also generic drugs of sofosbuvir and velpatasvir produced in other countries. The specifications of the Bangladesh Everest Pharmaceutical Factory are (400mg + 100mg) * 28 tablets per box, and the price is around RMB 850 (the price may fluctuate due to the exchange rate). The generic drugs produced abroad are basically the same as the original drugs at home and abroad.